PI3K inhibitors for R/R CLL
An overview of data for PI3K inhibitors for in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).
EP: 1.CLL: Evolution of Treatment
EP: 2.Molecular Testing for Newly Diagnosed CLL
EP: 3.Prognostic Factors in Chronic Lymphocytic Leukemia
EP: 4.CLL: Prognostic Markers
EP: 5.Long-Term Experience With Ibrutinib in CLL
EP: 6.BTK Inhibitors as Frontline Treatment for CLL
EP: 7.Safety and Efficacy of BTK Inhibitors in CLL
EP: 8.Mitigating Toxicities Associated With BTK Inhibitors
EP: 9.ALPINE Study: Zanubrutinib vs Ibrutinib in R/R CLL
EP: 10.BCL2 Inhibitors in Previously Untreated CLL
EP: 11.CLL Therapies: Novel Combinations
EP: 12.CLL: GLOW Trial Overview
EP: 13.CLL: BTK Inhibitors in the R/R Setting
EP: 14.High-Risk Patients With R/R CLL
EP: 15.CLL: Venetoclax in the R/R Setting
Now Viewing
EP: 16.PI3K inhibitors for R/R CLL
EP: 17.Emerging Agents for R/R CLL
EP: 18.CLL: Final Thoughts
Related Videos
Related Content
